Literature DB >> 7728844

Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty.

J M Wilson1, K G Dougherty, K O Ellis, J J Ferguson.   

Abstract

A discrete fall in the ACT (activated coagulation time) has been observed in patients with known activation of the coagulation cascade. Injury to the coronary artery resulting in thrombin activation, whether spontaneous as in the case of acute myocardial infarction or planned as with percutaneous transluminal coronary angioplasty (PTCA), may therefore be reflected in a change in ACT values. We reviewed the records of patients undergoing PTCA at St. Luke's Episcopal Hospital/Texas Heart Institute from January 1990 through December 1992 for information regarding ACT values and clinical events. A total of 469 patients, whose record contained adequate information for study inclusion, were divided into four separate groups: acute myocardial infarction (group I, n = 62), unstable angina with heparin therapy that was withdrawn at least 4 hr prior to PTCA (group II, n = 102), unstable angina with heparin therapy continued until the time of PTCA (group III, n = 154), and stable angina undergoing elective PTCA (group IV, n = 151). Heparin was discontinued 12-15 hr after the procedure in all but group I where anticoagulation was often maintained up to 72 hr. ACT values were measured prior to the PTCA procedure (baseline), after the initial heparin bolus of 10,000 U (postheparin) and approximately 12-18 hr after the procedure (heparin withdrawal).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7728844     DOI: 10.1002/ccd.1810340302

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  3 in total

1.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

2.  Angiographic and clinical outcomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Fadi Matar; Colleen Donoghue; Peter Rossi; Michel Vandormael; John T Sullebarger; Richard Kerenski; Werner Jauch; Kathy Gloer; George Ebra
Journal:  Can J Cardiol       Date:  2006-11       Impact factor: 5.223

3.  Activated clotting times in the setting of eptifibatide use during percutaneous coronary intervention.

Authors:  Harold L Dauerman; Steven A Ball; Robert J Goldberg; Melinda A Desourdy; Mark I Furman
Journal:  J Thromb Thrombolysis       Date:  2002-06       Impact factor: 2.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.